The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and ...

The FDA approved ribocilib (Kisqali; Novartis) with an aromatase inhibitor (AI) for breast cancer patients with HR-positive, HER2-negative stage II and III early breast cancer at high risk of ...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, ...

The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In ...

Today, the American Association for Cancer Research (AACR) released its 14th annual Cancer Progress Report, which provides the latest statistics on cancer incidence, mortality, and survivorship, and ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

Molecular Cancer Research publishes articles featuring novel, basic cancer research discoveries that prioritize broad molecular and cellular processes. Areas of emphasis include cell cycle and ...

Interested individuals should prepare and submit an application to Christine Battle, Publisher and Vice President, Scientific Publications, AACR via email ([email protected]) by Monday, ...